Axonal-Growth-Associated Intracellular Molecule in the Rat Central Nervous System Recognized by the Monoclonal Antibody 5H (Part 2 of 2)

1995 ◽  
Vol 17 (1) ◽  
pp. 43-46
Author(s):  
Hironobu Katsumaru ◽  
Taro Suzuki ◽  
Daisuke Unami ◽  
Fujio Murakami
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Axonal Growth

Axonal-Growth-Associated Intracellular Molecule in the Rat Central Nervous System Recognized by the Monoclonal Antibody 5H

1995 ◽  
Vol 17 (1) ◽  
pp. 38-46 ◽  
Author(s):  
Hironobu Katsumaru ◽  
Taro Suzuki ◽  
Daisuke Unami ◽  
Fujio Murakami
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Axonal Growth

A novel monoclonal antibody that recognizes human perivascular cells of the central nervous system under a specific immune reaction

2000 ◽  
Vol 20 (3) ◽  
pp. 216-220 ◽  
Author(s):  
Hideaki Yokoo ◽  
Koji Isoda ◽  
Mizuaki Sakura ◽  
Atsushi Sasaki ◽  
Junko Hirato ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Immune Reaction ◽  
Perivascular Cells ◽  
The Central Nervous System

Interleukin 6 in Cerebrospinal Fluid of Patients with Meningitis is not a Useful Diagnostic Marker in the Differential Diagnosis of Meningitis

1997 ◽  
Vol 34 (2) ◽  
pp. 165-169 ◽  
Author(s):  
L F López-Cortés ◽  
M Cruz-Ruiz ◽  
J Gómez-Mateos ◽  
D Jiménez-Hernández ◽  
P Viciana-Fernández ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Cerebrospinal Fluid ◽  
Nervous System ◽  
Differential Diagnosis ◽  
Interleukin 6 ◽  
Diagnostic Marker ◽  
Neurological Diseases ◽  
Central Nervous System Infections ◽  
Pyogenic Meningitis

We assayed interleukin 6 (IL-6) concentrations in cerebrospinal fluid (CSF) from patients affected by meningitis of different aetiologies, and verified whether IL-6 can be used as a diagnostic marker in the differential diagnosis of meningitis. We used a monoclonal antibody enzyme immunoassay to test 98 CSF samples classified as pyogenic (15), viral (15), self-resolving aseptic meningitis (20), other infectious meningitis (9), neoplastic (4) and normal CSF from patients with (20) and without (15) non-infectious neurological diseases. CSF IL-6 concentrations were increased in pyogenic meningitis (100%) and in more than 50% of viral and other subarachnoid space infections, and rarely in patients without central nervous system infections. Though patients affected by pyogenic meningitis showed the highest levels of CSF IL-6, only a cut-off point ≥10000 pg/mL was able to discriminate pyogenic meningitis from those of other aetiologies with a specificity ≥94% and a positive predictive value of ≥0·75 but the sensitivity was ≤60%. Therefore, CSF IL-6 concentration is not a good diagnostic marker in the differential diagnosis of meningitis.

scholarly journals Ixekizumab for patients with plaque psoriasis affected by multiple sclerosis

2021 ◽  
Author(s):  
Enrique Herrera-Acosta ◽  
Gustavo Guillermo Garriga Martina ◽  
Jorge Alonso Suárez-Pérez ◽  
Eliseo Alejandro Martínez-García ◽  
Enrique Herrera-Ceballos
Keyword(s):  
Multiple Sclerosis ◽  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Adverse Events ◽  
Plaque Psoriasis ◽  
Neurological Disease ◽  
Chronic Plaque Psoriasis ◽  
Demyelinating Disorder ◽  
The Central Nervous System

Multiple sclerosis is an autoimmune demyelinating disorder of the central nervous system that shares similar immunopathogenic mechanisms with chronic plaque psoriasis, such as the overexpression of the Th17 pathway. We report the case of a patient with multiple sclerosis and severe chronic plaque psoriasis successfully treated with ixekizumab (anti IL-17A and IL-17A/F monoclonal antibody). The treatment achieved a complete skin clearance (PASI 100 response) with no adverse events or evidence of progression of the neurological disease. Keywords: Psoriasis; Ixekizumab; Multiple sclerosis

The monoclonal antibody 69A1 recognizes an epitope found on neurones with axons that fasciculate but not on those with non-fasciculating processes

Development ◽  
1987 ◽  
Vol 100 (3) ◽  
pp. 489-500
Author(s):  
R. Pigott ◽  
A.M. Davies
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Peripheral Nervous System ◽  
Nerve Fibre ◽  
Surface Antigen ◽  
Cell Type ◽  
Fibre Bundles ◽  
Type Distribution

We have previously reported that the cell-type distribution and pattern of expression of the surface antigen recognized by the monoclonal antibody 69A1, suggests that it may be involved during the period of nerve fibre outgrowth and the formation of fibre bundles in the rat (Pigott & Kelly, 1986). In this current study, we have examined the expression of the epitope recognized by antibody 69A1 in regions of the rat central nervous system in which it is possible to distinguish between neurones with axons that fasciculate to form clearly defined fibre tracts and neurones with non-fasciculating processes. We have also examined antibody 69A1 labelling in several regions of the peripheral nervous system. We report that the 69A1 epitope is expressed on neurones with axons that fasciculate but is not found on neurones with short, non-fasciculating axons or on neurones without a morphologically identifiable axon. The antigen 69A1 has been purified and shown to be immunochemically closely related or identical to the L1 antigen.

scholarly journals PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation

Stroke ◽  
2015 ◽  
Vol 46 (10) ◽  
pp. 2926-2934 ◽  
Author(s):  
Sheetal Bodhankar ◽  
Yingxin Chen ◽  
Andrew Lapato ◽  
Abby L. Dotson ◽  
Jianming Wang ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Monoclonal Antibody ◽  
Nervous System ◽  
Ischemic Stroke ◽  
Central Nervous System Inflammation
Sign in / Sign up

Export Citation Format

Share Document